Reports Q2 revenue $110.7M, consensus $107.66M. “We had a strong performance in the first half of fiscal 2026, ending the second quarter with our thirteenth consecutive quarter of growth. Revenue exceeded guidance, coming in at $110.7 million, growth of over 19% compared to the second quarter of 2025,” said Emily Leproust, CEO. “As we look ahead, we remain focused on delivering consistent, measurable growth designed to scale over time. We expect to chart toward profitability while simultaneously building on the strong momentum we are seeing across the portfolio. We continue to anticipate achieving adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 while holding gross margin above 52% for the fiscal year.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- TWST Upcoming Earnings Report: What to Expect?
- Twist Bioscience price target raised to $55 from $50 at Barclays
- Twist Bioscience price target raised to $56 from $52 at Evercore ISI
- Twist Bioscience price target raised to $55 from $50 at Guggenheim
- Cathie Wood Pours $16M into Circle Stock, Dumps ROKU, TSM, TWST, BLSH